Chronic Idiopathic Constipation Drugs Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Drug class ( Serotonin-4 (5-Ht4) Receptor Agonist, Guanylate Cyclase-C Agonist, Laxatives, Emollients, Others ); End User ( Hospitals, Specialty Clinics, Others ), and geography
One of the most common gastrointestinal problems worldwide is constipation. Constipation, is characterized as decreased stool frequency or less than 3 times a week or difficulty passing stools or both. The duration of 3 days a week is different from that of different people. This could be a normal habit for some and any improvement or decrease in frequency in these people is known to be constipation. The chronic presence of these symptoms is known as Chronic Idiopathic Constipation (CIC). It is considered idiopathic since there is no clear cause of this form of constipation and it is not caused by the underlying condition or medication.
Factors driving the growth of the chronic idiopathic constipation drugs market are the growing prevalence of irritable bowel syndrome with constipation (IBS-C), coupled with growing geriatric population. However, low awareness about guidelines for the diagnosis and treatment of idiopathic constipation is expected to hamper the growth of the market. Moreover, rising use of opioid and adoption of unhealthy lifestyle and lack of physical activity is anticipated to boost the market growth.
The "Chronic Idiopathic Constipation Drugs Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of chronic idiopathic constipation drugs market with detailed market segmentation by drugs class and end user. The chronic idiopathic constipation drugs market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in chronic idiopathic constipation drugs market and offers key trends and opportunities in the market.
The chronic idiopathic constipation drugs market is segmented on the basis of drugs class and end user.
On the basis of drugs the market is sub segmented as Serotonin-4 (5-Ht4) receptor agonist, guanylate cyclase-c agonist, laxatives, emollients, and others. On the basis of surgery the market is sub segmented as laparoscopic rectopexy and lateral internal sphincterotomy.
On the basis of end user, the market is categorized as hospitals, specialty clinics, and others.
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the chronic idiopathic constipation drugs market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The chronic idiopathic constipation drugs market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting chronic idiopathic constipation drugs market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the chronic idiopathic constipation drugs market in these regions.
Get more information on this report :
The report covers key developments in the chronic idiopathic constipation drugs market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from chronic idiopathic constipation drugs market are anticipated to have lucrative growth opportunities in the future with the rising demand for chronic idiopathic constipation drugs in the global market. Below mentioned is the list of few companies engaged in the chronic idiopathic constipation drugs market.
The report also includes the profiles of key players in chronic idiopathic constipation drugs market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
Astellas Pharma, Inc.
Synergy Pharmaceuticals, Inc.
Boehringer Ingelheim International GmbH
Ironwood Pharmaceuticals, Inc.
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.
Get more information on this report :
The List of Companies
1. Astellas Pharma, Inc.
2. Synergy Pharmaceuticals, Inc.
3. Sanofi S.A.
4. Pfizer, Inc.
6. Boehringer Ingelheim International GmbH
7. GlaxoSmithKline Plc.
8. Bayer AG
9. Allergan Plc.
10. Ironwood Pharmaceuticals, Inc.